MAvatar is the first company in the world to construct disease models based on integrating single cell RNA sequencing and routine clinical data, as well as to exploit those models to find diagnostic combinations of variables for personalised medicine, as well as prediction of drug candidates.
One of the most important health care problems is that many patients do not respond to treatment. An important reason is that common diseases depend on altered interactions between thousands of genes and environmental factors, in combinations that differ between patients that do or do not respond. MAvatar combines genome-wide single cell analyses and routine clinical data to construct high-resolution models of individual patients, Medical Avatars (MAvatars). MAvatars can be analysed to find combinations of variables to personalise treatment, as well as to new therapeutic targets in patients that do not respond. We also develop software for clinical decision support based on the identified variables.
MAvatar originates from the Centre for Personalised Medicine (CPMed) at Linköping University, Sweden. CPMed aims to develop methods for personalised medicine and drug discovery based on combining genome-wide, bioinformatics, experimental and clinical studies. We have shown the feasibility of this in publications in leading journals like Science Translational Medicine in 2014, 2015 and 2017. Because disease-associated genes are variably expressed in different cell types, single cell RNA sequencing plays an important role. CPMed integrates multi-disciplinary experts with clinicians, and has a wide collaborative network based on coordinating two EU projects. CPMed and MAvatar are directed by professor Mikael Benson, who is an MD with almost twenty years of translational high-throughput research. Danuta Gawel is chief senior scientist, responsible for bioinformatics tool development at MAvatar.
We construct disease models based on integrating single cell and/or bulk RNA seq data with routine clinical data, such as laboratory tests, digital pathology or imaging. The models are constructed by a team that integrates genome-wide, bioinformatics, functional and clinical or mouse model studies. The same team can help design studies based on clients’ aims, and also develop new studies in an interactive process. MAvatar can also partner in EU consortia and contribute experience based on successfully applying for three EU grants. Clients include hospitals, academic researchers and pharmaceutical industries.
The MAvatar Team
The MAvatar team is a multi-disciplinary group of experts in bulk- and single cell omics, bioinformatics, functional and clinical research. To ensure clinical relevance and feasibility MAvatar is closely linked to clinicians in the university hospital as well as national and international colleagues.
MD, PhD (integromics)
MD, PhD (translational omics)
Bioinformatician, Chief scientific Officer)